-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

Benzinga·07/09/2026 15:36:41
Listen to the news
Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.